The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Results from the MONUMENTAL-3 study showed that the combination of talquetamab and daratumumab with or without pomalidomide (Tal-DP/Tal-D) significantly improved survival compared with daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma.
The investigational drug blocks the expression of HJV in order to reduce hepcidin. It is in mid-stage development by Disc Medicine. Updated data from the Phase 2 open label RALLY-MF study were presented at the EHA 2026 and ASCO 2026 meetings in June.
In this video from the 2026 ASCO Annual Meeting, Dr. Mascarenhas, a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses results from the phase 3 SENTRY trial.
In an analysis presented at ASCO 2026, Justin Watts, MD, of the University of Miami and colleagues explored what baseline factors — including sex, disease stage and molecular characteristics — were associated with longer-term responders who did not go on to receive a transplant.
At the 2026 ASCO Annual Meeting, Marc Hoffman, MD, of the University of Kansas Cancer Center, discusses results from the ongoing GOLSEEK-1 trial of golcadomide.
The anito-cel analysis covered 104 patients enrolled and leukapheresed in iMMagine-3 or GEM-AnitoFirst from September 2024 to October 2025. Anito-cel lots were successfully manufactured for all patients, and 101 out of 102 lots were manufactured successfully on the first pass.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
